BHVN vs LLY: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
LLY is the larger of the two ($1.20T market cap): the incumbent the market prices for continued execution (26.59x forward earnings, beta 0.39). BHVN is the smaller challenger ($1.94B), still expected to post a loss next year: more room to run, but more to prove. On the numbers, LLY leads on both counts: faster expected revenue growth (16% vs -38%) and expected profits next year, which BHVN does not have. The case for BHVN rests on its own driver (Taldefgrobep obesity readout, now in 2027): if you believe in that, BHVN fits; if you believe in what the numbers show today, LLY does.
BHVN vs LLY: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BHVN | LLY | What it tells you |
|---|---|---|---|
| Market cap | $1.94B | $1.20T | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -8.40 | 26.59 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 3.13 | 0.39 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 48% of range | 80% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how BHVN and LLY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BHVN and LLY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BHVN and LLY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Biohaven Ltd (BHVN) do?
Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies across neuroscience, immunology, obesity and oncology. It was created in 2022 when Pfizer acquired the original Biohaven's CGRP migraine business (including Nurtec ODT) for roughly $11.6 billion; the remaining non-CGRP pipeline was spun out into the current publicly traded Biohaven Ltd. Its programs include taldefgrobep alfa (a myostatin-activin pathway inhibitor being tested in obesity and spinal muscular atrophy), troriluzole (VYGLXIA, targeted at spinocerebellar ataxia), opakalim (BHV-7000, a Kv7 ion channel activator for focal epilepsy and depression), MoDE and TRAP extracellular degraders such as BHV-1300 (now in Phase 3 for Graves' disease) and BHV-1400 (IgA nephropathy), and antibody-drug conjugates such as BHV-1530.
What does Eli Lilly (LLY) do?
Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.
BHVN vs LLY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BHVN drivers: Taldefgrobep obesity readout, now in 2027; Opakalim epilepsy and depression, now with a regulatory delay.
- LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Biohaven has no product sales and posts large quarterly net losses (about $129 million in Q3 2026, against an analyst consensus that had expected licensing income to produce a small profit), so it depends on equity financing and licensing deals; equity raises dilute existing shareholders. For LLY, lLY trades at a premium valuation (about 44x trailing and 27x forward earnings, and roughly 14x sales, as of November 20, 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply.
BHVN or LLY: which should you pick?
If the story you believe is BHVN's (Taldefgrobep obesity readout, now in 2027), BHVN is the more direct way to own it; if it is LLY's (GLP-1 obesity and diabetes leadership), LLY is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BHVN and LLY guides.
BHVN vs LLY: the full fundamentals
BHVN. Biohaven trades as a pipeline-value biotech rather than on earnings, with a market cap near $1.9 billion and no product revenue. The quarterly loss has narrowed from about $173 million in Q3 2025 to about $129 million in Q3 2026 as research spending fell, but the licensing income analysts had pencilled into the third quarter did not appear because the Ono payment arrived after quarter end. Consensus now looks for fourth-quarter revenue of about $147 million and EPS of about $0.44 as deal payments are recognized. Cash of about $164 million at the end of September keeps financing and runway front of mind, which is why closing the SK Biopharmaceuticals deal matters.
LLY. At about $1,353 a share on November 20, 2026, Eli Lilly is valued near $1.2 trillion, roughly 44x trailing earnings and 27x the roughly $50.87 in EPS analysts expect for 2027. That premium rests on revenue growth near 39% in the latest quarter and margins (about 51% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the mean analyst target of about $1,470 sits roughly 9% above the price.
Headline figures (approximate, November 2026): BHVN shows market cap ~$1.9B, share price (nov 20, 2026) ~$12.85 (YTD ~+19%, 1y ~+34%), 52-week range ~$8.03 to ~$18.24, q3 2026 net loss ~$129M (EPS -$0.86 vs ~+$0.16 est.); LLY shows revenue (ttm) ~$86.5 billion, q3 2026 revenue ~$24.4 billion (up ~39% YoY), q3 2026 eps $7.48 vs ~$6.35 est., gross / operating margin (ttm) ~84% / ~51%.
The bottom line: BHVN vs LLY
BHVN and LLY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BHVN and LLY exposure against your real portfolio. It is not an investment adviser.
Wondering how BHVN or LLY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Biohaven Ltd
Ask Walnut's AI anything about BHVN and see how it fits what you own.
FAQ
What is the difference between BHVN and LLY?
+
Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies across neuroscience, immunology, obesity and oncology. Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BHVN or LLY the better stock?
+
Neither is universally better. LLY is the larger incumbent; BHVN is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BHVN or LLY?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BHVN and LLY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BHVN vs LLY?
+
BHVN: Biohaven has no product sales and posts large quarterly net losses (about $129 million in Q3 2026, against an analyst consensus that had expected licensing income to produce a small profit), so it depends on equity financing and licensing deals; equity raises dilute existing shareholders. Cash stood at about $164 million at the end of September 2026 against about $264 million of notes payable, before the $80 million Ono upfront received in October and before the SK Biopharmaceuticals deal, whose $350 million closing payment still depends on remaining conditions. The 2025 Complete Response Letter for troriluzole and the 2026 partial clinical hold on opakalim show regulatory outcomes can go against the company, and the troriluzole decision in early 2027 and several late-stage readouts are binary events that could sharply move the stock in either direction. The obesity field is intensely competitive and dominated by well-capitalized GLP-1 players, taldefgrobep's muscle-sparing thesis is still unproven in humans at scale, and its readout has slipped to 2027. Cash runway relative to a heavy research budget is a persistent concern that investors should monitor. LLY: LLY trades at a premium valuation (about 44x trailing and 27x forward earnings, and roughly 14x sales, as of November 20, 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence. The balance sheet has also become more leveraged as Lilly funds capacity: debt was about $49.5 billion against about $4.9 billion of cash at September 30, 2026, and trailing free cash flow of about $9.3 billion is far below operating cash flow of about $30.7 billion because of heavy capital spending. Revenue growth also slowed from about 48% in the second quarter to about 39% in the third as the base gets larger, and GAAP net income fell quarter over quarter, so the pace of growth is now part of the debate.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BHVN or LLY; figures are approximate and dated (as of November 2026). Verify current data before investing.